

**COMPOUNDED DRUG TESTING REPORT FY 2007**

In 2003 the Board initiated a program to test drug preparations compounded by pharmacies. All preparations are tested for potency and, if applicable, sterility and endotoxin. The tables below are for the fiscal year ending 6/30/07.

<b>Dosage Form</b>	<b>Tests Performed</b>
Capsule	37
Injection	7
I.V. solution	12
Oral solution	2
Oral suspension	140
Suppository	5
Tablet	2
Topical cream/ointment	1
Transdermal	6
Troche	1

<b>Test Results</b>	<b>Tests Performed</b>	<b>Percentage</b>
Satisfactory	162	76.1%
Unsatisfactory	51	23.9%
<b>Total</b>	213	100%

All unsatisfactory results were related to potency failures. An acceptable potency range is considered +/- 10% of the expected potency, unless a U.S.P. monograph states a different range for a specific preparation. Failing potency results ranged from 21.2% to 450.4%.

<b>Drugs with unsatisfactory results</b>
Azathioprine oral suspension
Baclofen suppositories
Biest/Progesterone capsules
Biest/Progesterone/DHEA capsules
Biest/Progesterone/Testosterone capsules
Boric Acid capsules
Captopril oral suspension
Carboplatin IV solution
Cisplatin IV solution
Clonidine injection
DHEA capsules
Diethylstilbestrol capsules
Enalapril oral suspension
Enalapril tablets
Histamine Diphosphate injection
Histamine injection
Ketoprofen transdermal

Lansoprazole oral suspension
Metronidazole oral suspension
Omeprazole oral suspension
Piroxicam capsules
Progesterone capsules
Progesterone suppositories
Progesterone troches
Progesterone/Melatonin/Hydroxytryptophan capsules
Rifampin oral suspension
Spirolactone/HCTZ oral suspension
Testosterone transdermal
Triest/DHEA capsules
Triest/Progesterone capsules
Triest/Progesterone/DHEA/Testosterone capsules

Pharmacies are notified of unsatisfactory results and asked to complete a quality assurance review of their compounding practices and provide a corrective action plan.